A Phase 2 interventional study of OLAPARIB in Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity, sponsored by AstraZeneca. Completed at 47 sites in 2 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2022-04-13.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 13th largest by enrollment, is one of 5 that started in 2016, is one of 32 in phase 2, and was the 26th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 272 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 97 across the 69 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 14th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2016, is one of 12 in phase 2, and was the 28th registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy.
This is a Phase II, open-label, non-randomized, multi-center study assessing the efficacy and safety of olaparib tablets 300 mg (two 150 mg tablets) given orally twice daily (bid) in subjects with platinum-sensitive or partially platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received at least 1 prior line of platinum-based chemotherapy.
The study will assess the effectiveness of olaparib tablets as measured by the objective response rate (ORR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, in subjects with germline BRCA mutations (gBRCAm), somatic BRCA mutations (sBRCAm), or potential aberrations in homologous recombination deficiency (HRD) as determined by myChoice® HRD, as well as in subjects without identifiable HRD. This study will utilize Myriad BRACAnalysis CDx® for germline BRCA analysis and a tumor test (myChoice® HRD) for tumor BRCA analysis and HRD status. Four cohorts will be identified based upon the genetic testing described above:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
germline BRCA mutant
Drug: OLAPARIB
somatic BRCA mutant, germline BRCA wild type
Drug: OLAPARIB
genomic instability positive and no BRCA mutation
Drug: OLAPARIB
genomic instability negative and no BRCA mutation
Drug: OLAPARIB
300 mg olaparib tablets taken orally twice daily
Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR)
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using ORR according to RECIST v1.1 criteria (Investigator determined)
Time frame: From first dose up until progression, or last evaluable assessment in the absence of progression (up to 36 months)
Duration of Response, for Those Subjects With a Confirmed Response of CR or PR
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using duration of response
Time frame: From the date of the measurement criteria for CR or PR are first met until the date of documented progression or death in the absence of disease progression (up to 36 months)
CA-125 Response Rate, Defined as the Percentage of Subjects With a CA-125 Response According to GCIG Criteria Divided by the Number of Subjects Evaluable for CA-125 Response
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using CA-125 response rate
Time frame: From baseline to Day 1 of each cycle and end of study treatment visit (up to 36 months)
Disease Control Rate Defined as the Percentage of Subjects Who Have a Best Overall Response of CR or PR or SD at Greater Than or Equal to 8 Weeks Divided by the Number of Subjects in the Efficacy Analysis Set, Prior to Any PD Event
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using disease control rate (DCR). DCR is defined as the percentage of subjects with a best overall response of CR or PR (at any time up to and including the defined analysis cut-off point) or who have demonstrated stable disease (SD) for at least 8 weeks from first dose, divided by the number of subjects in the efficacy analysis set.
Time frame: From first dose up until progression, or last evaluable assessment in the absence of progression
Progression Free Survival
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using progression free survival
Time frame: From first dose to earlier date of assessment of objective progression or death by any cause in the absence of progression (up to 36 months)
Time to Any Progression
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using time to any progression
Time frame: From first dose to earlier date of CA-125 progression or RECIST v1.1 progression, or death by any cause in absence of progression (up to 36 months)
Overall Survival
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using overall survival
Time frame: From date of first dose to date of death from any cause (up to 48 months)
HRD Status as Per HRRm Gene Panel Assessment Will be Correlated With Clinical Outcome (ORR) for Subjects Enrolled in the 2 Cohorts With BRCAwt (Cohorts 3 and 4)
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using HRRm gene panel status related to clinical outcome
Time frame: At baseline
| Milestone | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Unassigned |
|---|---|---|---|---|---|
| Started | 75 | 26 | 68 | 90 | 13 |
| Completed | 25 | 8 | 18 | 14 | 3 |
| Not completed | 50 | 18 | 50 | 76 | 10 |
| Withdrew: Withdrawn from study before data cut-off | 28 | 12 | 23 | 25 | 1 |
| Withdrew: Death | 20 | 5 | 23 | 47 | 7 |
| Withdrew: Withdrawal by subject | 1 | 0 | 3 | 4 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 0 |
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using ORR according to RECIST v1.1 criteria (Investigator determined)
| Percent | Cohort 1 | Cohort 2 | COHORT 3 | COHORT 4 | Unassigned |
|---|---|---|---|---|---|
| Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) | 69.3 (57.6 to 79.5) | 64.0 (42.5 to 82.0) | 29.4 (19.0 to 41.7) | 10.1 (4.7 to 18.3) | 30.8 (9.1 to 61.4) |
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using duration of response
| Months | Cohort 1 | Cohort 2 | COHORT 3 | COHORT 4 | Unassigned |
|---|---|---|---|---|---|
| Duration of Response, for Those Subjects With a Confirmed Response of CR or PR | 9.4 (7.5 to 12.5) | 14.7 (5.7 to NA) | 10.0 (5.6 to NA) | 5.3 (3.7 to 7.3) | 7.5 (6.0 to NA) |
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using CA-125 response rate
| Percent | Cohort 1 | Cohort 2 | COHORT 3 | COHORT 4 | Unassigned |
|---|---|---|---|---|---|
| CA-125 Response Rate, Defined as the Percentage of Subjects With a CA-125 Response According to GCIG Criteria Divided by the Number of Subjects Evaluable for CA-125 Response | 93.2 (81.3 to 98.6) | 70.0 (45.7 to 88.1) | 47.9 (33.3 to 62.8) | 26.6 (16.3 to 39.1) | 66.7 (34.9 to 90.1) |
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using disease control rate (DCR). DCR is defined as the percentage of subjects with a best overall response of CR or PR (at any time up to and including the defined analysis cut-off point) or who have demonstrated stable disease (SD) for at least 8 weeks from first dose, divided by the number of subjects in the efficacy analysis set.
| Percent | Cohort 1 | Cohort 2 | COHORT 3 | COHORT 4 | Unassigned |
|---|---|---|---|---|---|
| Disease Control Rate Defined as the Percentage of Subjects Who Have a Best Overall Response of CR or PR or SD at Greater Than or Equal to 8 Weeks Divided by the Number of Subjects in the Efficacy Analysis Set, Prior to Any PD Event | 96.0 (88.8 to 99.2) | 100.0 (86.3 to 100.0) | 79.4 (67.9 to 88.3) | 75.3 (65.0 to 83.8) | 92.3 (64.0 to 99.8) |
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using progression free survival
| Months | Cohort 1 | Cohort 2 | COHORT 3 | COHORT 4 | Unassigned |
|---|---|---|---|---|---|
| Progression Free Survival | 11 (8.3 to 12.2) | 10.8 (7.3 to NA) | 7.2 (5.3 to 7.6) | 5.4 (3.7 to 5.6) | 9.2 (3.5 to 12.7) |
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using time to any progression
| Months | Cohort 1 | Cohort 2 | COHORT 3 | COHORT 4 | Unassigned |
|---|---|---|---|---|---|
| Time to Any Progression | 10.9 (7.4 to 13.3) | 11.1 (6.6 to NA) | 7.2 (3.8 to 7.6) | 5.3 (3.7 to 5.5) | 7.3 (3.5 to 9.7) |
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using overall survival
| Months | Cohort 1 | Cohort 2 | COHORT 3 | COHORT 4 | Unassigned |
|---|---|---|---|---|---|
| Overall Survival | NA (29.2 to NA) | NA (NA to NA) | NA (22.8 to NA) | 23.8 (16.6 to 31.4) | 18 (8 to NA) |
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using HRRm gene panel status related to clinical outcome
| Percent | Cohort 3, HRRm Pos | Cohort 3, HRRm Neg | Cohort 4, HRRm Pos | Cohort 4, HRRm Neg |
|---|---|---|---|---|
| HRD Status as Per HRRm Gene Panel Assessment Will be Correlated With Clinical Outcome (ORR) for Subjects Enrolled in the 2 Cohorts With BRCAwt (Cohorts 3 and 4) | 11.1 (0.3 to 48.2) | 32.1 (20.3 to 46.0) | 8.3 (0.2 to 38.5) | 10.5 (4.7 to 19.7) |
Collected over Adverse events (AEs), serious AEs, AEs of special interest (AESIs), and AEs leading to discontinuation were collected from signature of informed consent for study participation. Treatment emerging AEs were reported from date of first dose of study treatment and continued throughout the active treatment period and the follow-up period 30 days after the last dose of olaparib. After the primary analysis data cut-off till study completion, only deaths, SAEs, AESIs and DAEs were collected/reported.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| COHORT 1 | 20/75 (26.7%) | 13/75 (17.3%) | 75/75 (100%) |
| COHORT 2 | 5/25 (20%) | 8/25 (32%) | 25/25 (100%) |
| COHORT 3 | 23/68 (33.8%) | 7/68 (10.3%) | 67/68 (98.5%) |
| COHORT 4 | 47/90 (52.2%) | 35/90 (38.9%) | 88/90 (97.8%) |
| UNASSIGNED | 7/13 (53.8%) | 6/13 (46.2%) | 12/13 (92.3%) |
| Event | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | UNASSIGNED |
|---|---|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 4/75 | 1/25 | 0/68 | 6/90 | 4/13 |
| BacteraemiaInfections and infestations | 0/75 | 0/25 | 0/68 | 0/90 | 1/13 |
| Strangulated incisional herniaInjury, poisoning and procedural complications | 0/75 | 0/25 | 0/68 | 0/90 | 1/13 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/75 | 0/25 | 0/68 | 0/90 | 1/13 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/75 | 0/25 | 0/68 | 0/90 | 1/13 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/75 | 0/25 | 0/68 | 5/90 | 0/13 |
| Intestinal obstructionGastrointestinal disorders | 1/75 | 0/25 | 1/68 | 4/90 | 0/13 |
| Acute myocardial infarctionCardiac disorders | 0/75 | 1/25 | 0/68 | 0/90 | 0/13 |
| Atrial fibrillationCardiac disorders | 0/75 | 1/25 | 0/68 | 0/90 | 0/13 |
| Atrioventricular blockCardiac disorders | 0/75 | 1/25 | 0/68 | 0/90 | 0/13 |
| Event | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | UNASSIGNED |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 50/75 | 20/25 | 42/68 | 60/90 | 8/13 |
| FatigueGeneral disorders | 50/75 | 15/25 | 43/68 | 50/90 | 9/13 |
| Abdominal painGastrointestinal disorders | 15/75 | 4/25 | 10/68 | 13/90 | 7/13 |
| VomitingGastrointestinal disorders | 21/75 | 12/25 | 15/68 | 35/90 | 6/13 |
| AnaemiaBlood and lymphatic system disorders | 18/75 | 7/25 | 14/68 | 31/90 | 5/13 |
| DiarrhoeaGastrointestinal disorders | 17/75 | 4/25 | 15/68 | 18/90 | 5/13 |
| Decreased appetiteMetabolism and nutrition disorders | 11/75 | 6/25 | 16/68 | 21/90 | 5/13 |
| Blood creatinine increasedInvestigations | 10/75 | 9/25 | 13/68 | 13/90 | 0/13 |
| HeadacheNervous system disorders | 19/75 | 8/25 | 13/68 | 11/90 | 1/13 |
| DyspepsiaGastrointestinal disorders | 7/75 | 3/25 | 9/68 | 11/90 | 4/13 |
| Age, Continuous(Age Continuous) | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Unassigned | Total |
|---|---|---|---|---|---|---|
| Mean | 60.7 ± 9.3 | 69.7 ± 9.0 | 63.2 ± 9.9 | 67.8 ± 9.5 | 69.8 ± 10.0 | 64.9 ± 10.1 |
| Sex/Gender, Customized(Participants) | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Unassigned | Total |
|---|---|---|---|---|---|---|
| Female | 75 | 26 | 68 | 90 | 13 | 272 |
| Race/Ethnicity, Customized(Participants) | COHORT 1 | COHORT 2 | COHORT 3 | COHORT 4 | Unassigned | Total |
|---|---|---|---|---|---|---|
| WHITE | 58 | 23 | 50 | 78 | 11 | 220 |
| BLACK OR AFRICAN AMERICAN | 7 | 0 | 5 | 5 | 0 | 17 |
| ASIAN | 6 | 3 | 11 | 6 | 2 | 28 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 | 0 | 0 | 0 |
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 1 | 0 | 0 | 1 |
| OTHER | 4 | 0 | 1 | 1 | 0 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2016 to primary completion in Dec 2020, 47 months.
Results were first posted in Apr 2022, 1 year 4 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 47 months is above that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib